DiaMonTech AG Receives 2.5 Million Euros in EU Funding

BERLIN, 16th OF NOVEMBER 2026

The Berlin-based startup DiaMonTech is developing a technology that uses infrared light to measure blood sugar levels through the skin—making it significantly easier for millions of people with diabetes to monitor their levels on a daily basis in the future. The company is now receiving 2.5 million euros from the European Innovation Council’s EIC Accelerator to further develop the technology. The goal: a prototype for a portable, smartphone-sized monitoring device. In the long term, the technology could also be integrated into wearables, making blood sugar monitoring even easier to incorporate into daily life. CEO and co-founder Thorsten Lubinski explains the technology’s potential and the development steps still ahead.

Reliably measuring blood sugar levels without having to draw blood—this has been a focus of research in medical technology for decades. The challenge lies in determining glucose levels through the skin with sufficient accuracy. For people with diabetes, who need to monitor their levels regularly, such technology could make life significantly easier. The Berlin-based medical technology company DiaMonTech has been working on such a solution since its founding and has already achieved promising clinical results with its larger D-Base measurement system. Now, the patented infrared technology is to be scaled down to the point where it can be used in a portable device. The company has secured 2.5 million euros in EU funding for this development phase. “Our goal is to make blood glucose monitoring without blood sampling so simple and reliable that it can be easily integrated into everyday life. We’ve already laid important groundwork for this with our larger monitoring system. Now we want to bring the technology into a portable format,” explains Thorsten Lubinski, CEO and co-founder of DiaMonTech.

EU Funding as a Sign of Confidence in Berlin’s Medical Technology Sector

DiaMonTech succeeded in securing funding for this project through a rigorous European selection process. The EIC Accelerator is part of the European research and innovation program Horizon Europe. It supports companies seeking to bring highly innovative technologies—which carry high development risks—to market readiness. “The EIC Accelerator is the ‘Champions League’ of European funding instruments for SMEs. The competition is fierce, and the success rate is around two percent,” explains Anke Wiegand, coordinator of the Enterprise Europe Network. In addition to an innovative deep-tech solution, a clear market entry strategy and a team capable of successfully implementing the development are also crucial, she adds. DiaMonTech meets these requirements, according to Wiegand. The Enterprise Europe Network Berlin-Brandenburg, as part of Berlin Partner, supported DiaMonTech in submitting its application. The funding agreement was signed in September 2026, and the project launched on October 1.

Clinically Tested Technology Set to Go Mobile

DiaMonTech uses mid-infrared light to measure glucose through the skin. The larger D-Base measurement system has already been tested in a blinded clinical trial at the Institute for Diabetes Technology in Ulm. In that trial, the system achieved a level of measurement accuracy comparable to that of early minimally invasive systems for continuous glucose monitoring. With this funding, DiaMonTech is now developing the more compact D-Pocket. In the future, users will be able to place a finger or their wrist on a sensor to take a reading and see their blood glucose level after just a few seconds. To achieve this, the optical and electronic measurement components must be further miniaturized and integrated into a single device. A prototype is scheduled to be developed within the 18-month funding project. Further technical developments, clinical validation, and regulatory processes are required before the device is ready for the market. In the long term, the technology could also be used in wearables. While such devices have so far primarily tracked steps, heart rate, or sleep, additional health metrics such as glucose could be added in the future. A study published in June 2026 by researchers at the University Medical Center Hamburg-Eppendorf shows that medical applications are generating interest: 42 percent of the non-users of wearables surveyed cited the need for medical monitoring as a possible reason for using such a device in the future.

About DiaMonTech

DiaMonTech AG, headquartered in Berlin, is a technology leader in the field of non-invasive glucose monitoring. Using patented infrared technology, DiaMonTech offers a pain-free, accurate, and user-friendly alternative to conventional methods. The company is working to miniaturize its technology for integration into wearables and mobile devices. ‍

Press Contact:

Denitsa Tuparova
Fullstop Public Relations
d.tuparova@fullstoppr.com
T.:+49 1515 3549 863

‍

‍

Stay tuned and get updates.

Notify Me